Antisense Technology
Egr-1 inhibition reverses the transformation of prostate cancer cells
Published in Cancer Weekly, September 2nd, 2003
According to recent research published in the journal Oncogene, "transcription factor early growth response-1 (Egr-1) is a crucial regulator of cell growth, differentiation and survival. Several observations suggest that Egr-1 is growth promoting in prostate cancer cells and that blocking its function may impede cancer progression. To test this hypothesis, we developed phosphorothioate antisense oligonucleotides that efficiently inhibit Egr-1 expression without altering the expression of other family members Egr-2, Egr-3 and Egr-4."
"In TRAMP mouse-derived prostate cancer...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-09-02)
More Articles from Cancer Weekly
- Genomics
Tumor and drug-resistant genomes can be shaped by instability and selection - Oncology
COX-2 causes prostaglandin E2 to modulate pancreatic cancer angiogenesis - Leukemia
Childhood survivors not receiving radiation have same life expectancy as general population - Non-Hodgkin Lymphoma
Delaying chemotherapy could be best treatment option - Pancreatic Cancer
Novel targets for aberrant methylation in pancreatic carcinoma found - Prostate Cancer
Chronic zinc oversupply may play a role in prostate carcinogenesis - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
